CN114533836B - 一种不影响bFGF活性的制剂及其制备方法和应用 - Google Patents
一种不影响bFGF活性的制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN114533836B CN114533836B CN202111640427.4A CN202111640427A CN114533836B CN 114533836 B CN114533836 B CN 114533836B CN 202111640427 A CN202111640427 A CN 202111640427A CN 114533836 B CN114533836 B CN 114533836B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- bfgf
- wound repair
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 103
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 title claims abstract description 66
- 230000000694 effects Effects 0.000 title claims abstract description 48
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 title claims abstract 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 11
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 11
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 11
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 11
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 11
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 11
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 11
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 11
- 229940116229 borneol Drugs 0.000 claims abstract description 11
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 10
- 244000234609 Portulaca oleracea Species 0.000 claims abstract description 10
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 10
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 10
- 241000972672 Phellodendron Species 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 239000011259 mixed solution Substances 0.000 claims description 42
- 230000037314 wound repair Effects 0.000 claims description 28
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 206010052428 Wound Diseases 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 7
- 230000002745 absorbent Effects 0.000 claims description 6
- 239000002250 absorbent Substances 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002390 adhesive tape Substances 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 9
- 230000035876 healing Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 4
- 230000003467 diminishing effect Effects 0.000 abstract description 3
- 230000036573 scar formation Effects 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 239000000645 desinfectant Substances 0.000 abstract description 2
- 230000002070 germicidal effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 45
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 31
- 241000245665 Taraxacum Species 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241000218691 Cupressaceae Species 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101001051969 Bos taurus Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 241000208682 Liquidambar Species 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 240000004824 Trimezia steyermarkii Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- NEMNPWINWMHUMR-UHFFFAOYSA-N rafoxanide Chemical compound OC1=C(I)C=C(I)C=C1C(=O)NC(C=C1Cl)=CC=C1OC1=CC=C(Cl)C=C1 NEMNPWINWMHUMR-UHFFFAOYSA-N 0.000 description 1
- 229950002980 rafoxanide Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及医药技术领域，具体涉及一种不影响bFGF活性的制剂及其制备方法和应用。所述不影响bFGF活性的制剂的原料按重量份计，包括马齿苋9～13份、蒲公英8～12份、金银花8～12份、黄柏8～12份、鱼腥草5～9份、黄连6～10份、野菊花5～9份、艾叶8～12份、柴胡6～10份、薄荷叶4～8份、如意草6～10份和冰片4～8份。本发明提供了一种不影响bFGF活性的制剂，制剂原料的各组分协同作用，对伤口创面具有消炎杀菌的作用。而现有技术中的杀菌剂或消毒产品会影响bFGF的生物活性。本发明将制剂与bFGF联用，用于伤口创面的治疗，既可以消炎抗菌，又可以促进创面愈合，具有减少疤痕生成的功效。
Description
技术领域
本发明涉及医药技术领域，具体涉及一种不影响bFGF活性的制剂及其制备方法和应用。
背景技术
创面是正常皮肤(组织)在外界致伤因子如外科手术、外力、热、电流、化学物质、低温以及机体内在因素如局部血液供应障碍等作用下所导致的损害。常伴有皮肤完整性的破坏以及一定量正常组织的丢失，同时，皮肤的正常功能受损。创面修复过程首先需保护创面、防止细菌感染，然后抑制创面出血，最后促进创面细胞层面愈合。然而现有的创面修复产品一般只具有灭菌止血的功效，难以使创面快速愈合。
碱性成纤维细胞生长因子(bFGF)具有促进细胞分裂和增殖、促进血管生成、营养神经元、调节细胞代谢等功能，已广泛应用于五官科、烧伤科、整形美容科等科室，对伤口的修复作用已经通过临床验证。碱性成纤维细胞生长因子(bFGF)是一种促细胞生长作用很强的多肽细胞生长因子，由146个氨基酸组成，分子量为16.5KD，对酸、热敏感，对胰蛋白酶、糜蛋白酶和V8蛋白酶敏感，pH＜4时失活，在-70℃可以保存几年，4℃可以保存一周。因此，生长因子具有较强的促进伤口愈合功能，可用于创面修复。
然而，由于创面修复过程需要对伤口进行消毒，在临床常用的消毒产品如酒精、碘酒、双氧水等消毒后的创面环境会使生长因子失活，进而导致其功效下降。当生长因子与阳离子表面活性剂类广谱杀菌剂(如苯扎氯铵)联用时，更会严重影响生长因子的活性。
发明内容
有鉴于此，有必要提供一种不影响bFGF活性的制剂及其制备方法和应用。所述制剂在不影响bFGF活性的基础上，还具有消炎抗菌功能，与bFGF联用既可以消炎抗菌，又可以促进创面愈合，具有减少疤痕生成的功效。
本发明的第一个目的在于提供一种不影响bFGF活性的制剂，所述制剂具有消炎抗菌功能；
本发明的第二个目的在于提供一种不影响bFGF活性的制剂的制备方法；
本发明的第三个目的在于提供一种不影响bFGF活性的制剂的应用，将该制剂与bFGF联用后制备成混合溶液，所述混合溶液可用于创面修复。
为实现上述第一个目的，本发明采取以下的技术方案：
一种不影响bFGF活性的制剂，所述制剂的原料包括马齿苋、蒲公英、金银花、黄柏、鱼腥草、黄连、野菊花、艾叶、柴胡、薄荷叶、如意草、冰片中的至少一种。
进一步的，所述制剂的原料按重量份计，包括马齿苋9～13份、蒲公英8～12份、金银花8～12份、黄柏8～12份、鱼腥草5～9份、黄连6～10份、野菊花5～9份、艾叶8～12份、柴胡6～10份、薄荷叶4～8份、如意草6～10份和冰片4～8份中的至少一种。
优选的，所述制剂的原料按重量份计，包括马齿苋9～13份、蒲公英8～12份、金银花8～12份、黄柏8～12份、鱼腥草5～9份、黄连6～10份、野菊花5～9份、艾叶8～12份、柴胡6～10份、薄荷叶4～8份、如意草6～10份和冰片4～8份。
为实现上述第二个目的，本发明采取以下的技术方案：
一种不影响bFGF活性的制剂的制备方法，所述制备方法为按重量份称取制剂原料，粉碎，制备成混合物，然后加水煎煮、浓缩后过滤。
进一步的，煎煮时混合物与水的比例为1:10～100(g/mL)。
进一步的，浓缩程度为混合物与水的比例为1：1～5(g/mL)。
进一步的，过滤为先经多层纱布过滤，再经0.45μm的滤膜过滤。
优选的，所述多层纱布为10层。
为实现本发明的第三个目的，本发明采取以下的技术方案：
一种不影响bFGF活性的制剂的应用，将制剂与bFGF混合制备成混合溶液。混合溶液可用于创面修复。
进一步的，所述混合溶液进一步制成包括但不限于创可贴、敷料、冻干粉或喷雾剂的产品形式。
进一步的，所述bFGF为人碱性成纤维细胞生长因子或牛碱性成纤维细胞生长因子。
进一步的，制剂与bFGF混合体积比例为(0.5～2)：1。
优选的，所述bFGF的浓度为1mg/mL。
进一步的，制剂与bFGF混合后的混合溶液需置于棕色西林瓶中，在2～8℃下储存。
优选的，所述储存时间为0～7d。
进一步的，所述创可贴的制备方法为使用医用平布胶布和吸水垫制成创可贴基础材料，取制剂与bFGF的混合溶液200μL至吸水垫中。
进一步的，所述冻干粉的制备方法为将制剂与bFGF的混合溶液冻干即得。
此外，本发明还提供一种不影响bFGF活性的制剂，所述制剂在与bFGF混合后制备成混合溶液，混合溶液可有效治疗糖尿病足溃疡。
一种不影响bFGF活性的制剂，制剂的原料包括马齿苋、蒲公英、金银花、黄柏、鱼腥草、黄连、野菊花、艾叶、柴胡、薄荷叶、如意草，冰片，栀子，黄芪，姜黄，苍术、路路通、血竭、西洋参、当归、没药、乳香、沉香、西红花中的至少一种。
进一步的，制剂的原料按重量份计，包括1～100份马齿苋、1～100份蒲公英、1～100份金银花、1～100份黄柏、1～100份鱼腥草、1～100份黄连、1～100份野菊花、1～100份艾叶、1～100份柴胡、1～100份薄荷叶、1～100份如意草，1～100份冰片、1～100份栀子、1～100份黄芪、1～100份姜黄、1～100份苍术、1～100份路路通、1～100份血竭、1～100份西洋参、1～100份当归、1～100份没药、1～100份乳香、1～100份沉香、1～100份西红花中的至少一种。
本发明的有益效果为：
本发明提供了一种不影响bFGF活性的制剂，制剂原料的各组分协同作用，对伤口创面具有消炎杀菌的作用。而现有技术中的杀菌剂或消毒产品会影响bFGF的生物活性。本发明将制剂与bFGF联用制备成混合溶液，用于伤口创面的治疗，既可以消炎抗菌，又可以促进创面愈合，具有减少疤痕生成的功效。
附图说明
图1为本发明抑菌环测试图；
图2为本发明生物活性测试图；
图3为本发明实施例2制备的制剂与人碱性成纤维细胞生长因子的混合溶液在不同天数下储存后的抑菌性能图；
图4为本发明实施例2制备的制剂与人碱性成纤维细胞生长因子的混合溶液在不同天数下储存后的生物活性数据图；
图5为小鼠普通创面伤口的在不同治疗天数下的愈合情况。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚，下面将结合本发明实施例，对本发明的技术方案作进一步清楚、完整地描述。需要说明的是，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明所用人碱性成纤维细胞生长因子为盖扶，规格：20000IU。
实施例1
一种不影响bFGF活性的制剂，所述制剂的原料按重量份计，包括马齿苋10份、蒲公英10份、金银花10份、黄柏10份、鱼腥草7份、黄连8份、野菊花7份、艾叶10份、柴胡8份、薄荷叶6份、如意草8份和冰片6份。
所述制剂采用如下方法制备：
按上述重量份计，将各个原料粉碎，制备成混合物；然后加水煎煮，混合物与水的比例为1:20(g/mL)，浓缩至混合物与水的比例为1：2(g/mL)后过滤；过滤为先经10层纱布过滤，再经0.45μm的滤膜过滤。
实施例2
一种不影响bFGF活性的制剂的应用，将不影响bFGF活性的制剂与bFGF混合，制备成混合溶液。具体为将实施例1制备的不影响bFGF活性的制剂与人碱性成纤维细胞生长因子按体积比为0.5：1混合，得到用于创面修复的混合溶液，其中人碱性成纤维细胞生长因子浓度为1mg/mL。
实施例3
一种不影响bFGF活性的制剂的应用，将不影响bFGF活性的制剂与bFGF混合，制备成混合溶液。具体为将实施例1制备的不影响bFGF活性的制剂与人碱性成纤维细胞生长因子按体积比为1：1混合，得到用于创面修复的混合溶液，人碱性成纤维细胞生长因子浓度为1mg/mL。
实施例4
一种不影响bFGF活性的制剂的应用，将不影响bFGF活性的制剂与bFGF混合，制备成混合溶液。具体为将实施例1制备的不影响bFGF活性的制剂与人碱性成纤维细胞生长因子按体积比为2：1混合，得到用于创面修复的混合溶液，人碱性成纤维细胞生长因子浓度为1mg/mL。
实施例5
一种创可贴，其制备方法为使用医用平布胶布和吸水垫制成创可贴基础材料，取实施例2制备的用于创面修复的混合溶液200μL至吸水垫中。
实施例6
一种冻干粉，其制备方法为将实施例2制备的用于创面修复的混合溶液冻干即得。
对比例1
一种制剂的应用，将制剂与人碱性成纤维细胞生长因子按体积比为0.5：1混合，得到混合溶液，其中人碱性成纤维细胞生长因子浓度为1mg/mL。所述制剂的原料按重量份计，包括马齿苋10份、金银花10份、黄柏10份、鱼腥草7份、黄连8份、野菊花7份、艾叶10份、柴胡8份、薄荷叶6份、如意草8份和冰片6份。所述制剂的制备方法同实施例1。
对比例2
一种制剂的应用，将制剂与人碱性成纤维细胞生长因子按体积比为0.5：1混合，得到混合溶液，其中人碱性成纤维细胞生长因子浓度为1mg/mL。所述制剂的原料按重量份计，包括蒲公英10份、金银花10份、黄柏10份、鱼腥草7份、黄连8份、野菊花7份、艾叶10份、柴胡8份、薄荷叶6份、如意草8份和冰片6份。制备方法同实施例1。
对比例3
一种制剂的应用，将制剂与人碱性成纤维细胞生长因子按体积比为0.5：1混合，得到混合溶液，其中人碱性成纤维细胞生长因子浓度为1mg/mL。所述制剂的原料按重量份计，包括马齿苋10份、蒲公英10份、黄柏10份、鱼腥草7份、黄连8份、野菊花7份、艾叶10份、柴胡8份、薄荷叶6份、如意草8份和冰片6份。制备方法同实施例1。
对比例4
一种制剂的应用，将制剂与人碱性成纤维细胞生长因子按体积比为0.5：1混合，得到混合溶液，其中人碱性成纤维细胞生长因子浓度为1mg/mL。所述制剂的原料按重量份计，包括马齿苋10份、蒲公英10份、金银花10份、鱼腥草7份、黄连8份、野菊花7份、艾叶10份、柴胡8份、薄荷叶6份、如意草8份和冰片6份。制备方法同实施例1。
对比例5
一种制剂的应用，将制剂与人碱性成纤维细胞生长因子按体积比为0.5：1混合，得到混合溶液，其中人碱性成纤维细胞生长因子浓度为1mg/mL。所述制剂的原料按重量份计，包括马齿苋10份、蒲公英10份、金银花10份、黄柏10份、鱼腥草7份、黄连8份、野菊花7份、艾叶10份、薄荷叶6份、如意草8份和冰片6份。制备方法同实施例1。
实验数据
一、抑菌环测试
分别取实施例2、对比例1～5制备的制剂与人碱性成纤维细胞生长因子的混合溶液200μL滴至大小相同的吸水垫中，测试抑菌性能。以10％双氧水200μL为阳性对照组，无菌灭菌水200μL为阴性对照组。抑菌测试方法为：用无菌棉拭子蘸取浓度为5×105cfu/mL～5×106cfu/mL金黄色葡萄球菌悬液，在营养琼脂培养基平板表面均匀涂抹3次，盖好平皿，置室温干燥5min。分别将含有不同混合溶液的吸水垫贴放于平板表面，轻压使其贴紧，盖好平皿，置37℃培养箱培养18h观察结果，用游标卡尺测量抑菌环的直径(包括贴片)并记录。抑菌结果如图1和表1所示，图1和表1中a为阳性对照组，b为阴性对照组，c～h分别对应为实施例2、对比例1～5。
表1
由图1和表1可知，本发明实施例2制备的制剂与bFGF混合溶液抑菌环最大，与阳性对照组抑菌效果相当，说明实施例2制备的混合溶液中各个组分协同作用，具有最好的抑菌效果。
二、生物活性测试
将人碱性成纤维细胞生长因子原液、人碱性成纤维细胞生长因子与双氧水按体积比为1：1混合制备的混合溶液、人碱性成纤维细胞生长因子与75％乙醇按体积比为1：1混合制备的混合溶液、实施例2～4制备的制剂与人碱性成纤维细胞生长因子的混合溶液分别作为样品1～6，取以上样品相同酶活单位剂量用Balb/c 3T3细胞测活性。测试结果如图2所示。
由图2可知，与人碱性成纤维细胞生长因子原液相比，本发明实施例2～4提供的制剂与人碱性成纤维细胞生长因子的混合溶液中生长因子的生物活性无明显差距，仍能在一定程度上保证生长因子的生物活性，而其他的抗菌剂如双氧水、乙醇会严重抑制生长因子的生物活性。
三、储存时间测试
将实施例2制备的制剂与人碱性成纤维细胞生长因子的混合溶液分别在2～8度下分别储存3d、7d、10d、20d和30d，测试经长时间储存后本发明制剂与人碱性成纤维细胞生长因子的混合溶液的抗菌性能以及生物活性。其中抗菌性能测试方法按照《消毒技术规范》2002年版2.1.11.3.2的抑菌性能测试方法进行实验，并按照此标准的公式计算样品对金黄色葡萄球菌的抑菌率。生物活性测试方法同上。测试结果分别如图3和图4所示。
由图3和图4可知，随着储存时间的增加，实施例2制备的制剂与人碱性成纤维细胞生长因子的混合溶液的抑菌性能和生物活性逐渐下降。储存时间超过7天后，生物活性大幅度下降。因此本发明的制剂与人碱性成纤维细胞生长因子的混合后，优选在0～7d内使用。
四、对小鼠普通创面愈合的修复
1.取SPF级C57BL/6小鼠40只，雌雄各半(南方医科大学动物实验中心提供)，八周龄，体重17～25g，随机分为5组，每组8只，分别对应5组样品进行试验。
2.建造模型方法：腹腔注射5％水合氯醛0.08mL·(10g)-1麻醉，用酒精棉球消毒后背部皮肤，用无菌手术剪刀剪去直径约1.5cm的圆形皮肤。当天分别用棉签将5组样品均匀涂满创面，不包扎。为防止动物之间打斗摩擦引起伤口感染，小鼠均单笼饲养。
3.组1样品为实施例3中不影响bFGF活性的制剂与bFGF混合制备成的混合溶液，组2样品为生理盐水，组3样品为实施例1中不影响bFGF活性的制剂，组4为20000IU规格的盖扶产品，组5样品为碘伏。小鼠用药时间为3天，每天9:00用药。每天观察伤口的愈合情况，记录伤口开始愈合(创面变硬缩紧)和基本愈合的时间(创面缩小至5mm)，并在第3天、第6天、第9天、第12天、第15天分别拍照记录伤口复原情况。第16天小鼠处死。实验结果分别如表2和图5所示。
从表2和图5可知，与组2样品相比，组4、组3以及组1的样品均能显著缩短伤口创面开始愈合时间，特别是组1的样品能显著缩短基本愈合时间。
表2
*表示P<0.05，**表示P<0.01。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对本发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种创面修复、不影响bFGF活性的制剂，其特征在于，按重量份计，制剂的原料药：马齿苋9~13份、蒲公英8~12份、金银花8~12份、黄柏8~12份、鱼腥草5~9份、黄连6~10份、野菊花5~9份、艾叶8~12份、柴胡6~10份、薄荷叶4~8份、如意草6~10份和冰片4~8份。
2.权利要求1所述的创面修复、不影响bFGF活性的制剂的制备方法，其特征在于，所述制备方法为按重量份称取制剂原料药，粉碎，制备成混合物，然后加水煎煮、浓缩后过滤。
3. 根据权利要求2所述的创面修复、不影响bFGF活性的制剂的制备方法，其特征在于，煎煮时混合物与水的比例为1: （10~100）；浓缩程度为混合物与水的比例为1：（1~5）。
4.根据权利要求3所述的创面修复、不影响bFGF活性的制剂的制备方法，其特征在于，过滤为先经多层纱布过滤，再经0.45μm的滤膜过滤。
5.权利要求1所述的创面修复、不影响bFGF活性的制剂或权利要求2~4任意一项所述的制备方法制备的创面修复、不影响bFGF活性的制剂在制备创面修复产品中的应用，其特征在于，将制剂与bFGF混合制备成混合溶液。
6.根据权利要求5所述的创面修复、不影响bFGF活性的制剂在制备创面修复产品中的应用，其特征在于，所述创面修复产品包括但不限于创可贴、敷料、冻干粉或喷雾剂的产品形式。
7.根据权利要求5所述的创面修复、不影响bFGF活性的制剂在制备创面修复产品中的应用，其特征在于，制剂与bFGF混合体积比例为（0.5~2）：1。
8.根据权利要求5所述的创面修复、不影响bFGF活性的制剂在制备创面修复产品中的应用，其特征在于，所述bFGF的浓度为1mg/mL。
9.根据权利要求5所述的创面修复、不影响bFGF活性的制剂在制备创面修复产品中的应用，其特征在于，制剂与bFGF混合后的混合溶液需置于棕色西林瓶中，在2~8℃下储存。
10.根据权利要求6所述的创面修复、不影响bFGF活性的制剂在制备创面修复产品中的应用，其特征在于，所述创可贴的制备方法为使用医用平布胶布和吸水垫制成创可贴基础材料，取混合溶液200μL至吸水垫中；所述冻干粉的制备方法为将混合溶液冻干即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111640427.4A CN114533836B (zh) | 2021-12-29 | 2021-12-29 | 一种不影响bFGF活性的制剂及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111640427.4A CN114533836B (zh) | 2021-12-29 | 2021-12-29 | 一种不影响bFGF活性的制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114533836A CN114533836A (zh) | 2022-05-27 |
| CN114533836B true CN114533836B (zh) | 2023-01-31 |
Family
ID=81669637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111640427.4A Active CN114533836B (zh) | 2021-12-29 | 2021-12-29 | 一种不影响bFGF活性的制剂及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114533836B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186767A (zh) * | 2018-02-13 | 2018-06-22 | 福建省泊霖生态农业有限公司 | 一种湿润修复因子组合物及其制作方法 |
| CN108272959A (zh) * | 2018-03-26 | 2018-07-13 | 华南农业大学 | 一种复方中药及其制备方法和应用 |
| CN110403998A (zh) * | 2019-09-02 | 2019-11-05 | 贾仁川 | 一种抗痘与修复痘肌的组合物、中药提取物及中药制剂 |
-
2021
- 2021-12-29 CN CN202111640427.4A patent/CN114533836B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186767A (zh) * | 2018-02-13 | 2018-06-22 | 福建省泊霖生态农业有限公司 | 一种湿润修复因子组合物及其制作方法 |
| CN108272959A (zh) * | 2018-03-26 | 2018-07-13 | 华南农业大学 | 一种复方中药及其制备方法和应用 |
| CN110403998A (zh) * | 2019-09-02 | 2019-11-05 | 贾仁川 | 一种抗痘与修复痘肌的组合物、中药提取物及中药制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114533836A (zh) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davis et al. | Wound healing. Oral and topical activity of Aloe vera | |
| CN105833279B (zh) | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 | |
| CN104688810A (zh) | 一种基于天然植物原料的抗菌组合物及其应用 | |
| CN104688811A (zh) | 一种基于天然植物原料的祛痘组合物及其应用 | |
| CN110731921A (zh) | 具有祛痘功效的皮肤外用组合物 | |
| CN103025386A (zh) | 用于治疗微生物感染的罗望子种子多糖 | |
| CN106728727A (zh) | 一种治疗疮疡的药膏及其制备方法 | |
| CN101406557A (zh) | 一种治疗烧伤、烫伤及多种皮肤损伤的外用中药 | |
| CN104306358A (zh) | 止痒祛疤涂膜剂 | |
| WO2014041440A1 (en) | Honey-based dressing for the treatment of wounds and burns | |
| CN105250696A (zh) | 一种促进皮肤伤口愈合的中药凝胶剂及其制备方法 | |
| CN112245497A (zh) | 一种杀菌消炎、促进伤口愈合的中药制剂及其制备方法 | |
| Doanh et al. | The use of a water extract from the bark of Choerospondias axillaris in the treatment of second decree burns | |
| Lee et al. | Evaluation of Melia azedarach extract-loaded poly (vinyl alcohol)/pectin hydrogel for burn wound healing | |
| CN108392672A (zh) | 三七海藻凝胶敷料及其制备方法 | |
| TWI825362B (zh) | 乳酸菌醱酵產物用於製備促進皮膚創傷癒合之外用組成物的用途 | |
| CN114533836B (zh) | 一种不影响bFGF活性的制剂及其制备方法和应用 | |
| CN111166929A (zh) | 一种湿性创口敷料及其制备方法 | |
| CN117338691A (zh) | 控油组合物及其制备方法 | |
| CN100393332C (zh) | 消肿拔毒生肌膏 | |
| CN107595819B (zh) | 一种纳米金刚石改性液体创可贴及其制备方法 | |
| CN1177490A (zh) | 烧伤红药油膏 | |
| CN1058619C (zh) | 一种消炎止痛烧伤药膏 | |
| CN101332286B (zh) | 一种治疗皮肤病的中药组合物及其制备方法 | |
| CN108392572B (zh) | 一种祛瘀生肌敛疮止疼的膏药及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A formulation that does not affect the activity of bFGF and its preparation method and application Granted publication date: 20230131 Pledgee: Agricultural Bank of China Limited Foshan Zumiao Sub-branch Pledgor: Long peptide biopharmaceutical Co.,Ltd. Registration number: Y2024980000968 |